

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/594,826
				Filing Date	July 17, 2007
				First Named Inventor	Lazarus et al.
				Art Unit	1644
				Examiner Name	Ronald B. Schwadron
(Use as many sheets as necessary)				Attorney Docket Number	1408/6
Sheet	1	of	1		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	Bussell, J.B., "The use of intravenous gamma-globulin in idiopathic thrombocytopenic purpura," Clinical Immunology and Immunopathology. Vol. 53, No. 2 pgs. S147-S155 (1989) [ABSTRACT].	
	2	de Fougerolles et al., "Regulation of inflammation by collagen-binding integrins $\alpha 1\beta 1$ and $\alpha 2\beta 1$ in models of hypersensitivity and arthritis," J. Clin. Invest. Vol. 105, No. 6 pgs. 721-729 (2000).	
	3	International Search Report corresponding to International Application No. PCT/CA2005/000472, filed March 30, 2005 by Lazarus et al., dated July 27, 2005.	
	4	Lazarus et al., "Monoclonal antibodies which mimic the action of intravenous immunoglobulin (mIVIG) can inhibit immune thrombocytopenia," Blood. Vol. 98, No. 11 pg. 441a (2001) [ABSTRACT].	
	5	Notification of Transmittal of International Preliminary Report on Patentability (Chapter I of the Patent Cooperation Treaty) corresponding to International Application No. PCT/CA2005/000472, filed March 30, 2005 by Lazarus et al., dated July 28, 2006.	
	6	Pecorino, Lauren, "Stem Cells for Cell-Based Therapies," < <a href="http://www.actionbioscience.org/biotech/pecorino2.html">http://www.actionbioscience.org/biotech/pecorino2.html</a> > (July 2001) (last visited January 11, 2005).	
	7	Reddy, Vijay, "Will Dendritic Cell-Based Therapies Have a Role in Leukemia Therapy?" Invited oral presentation, Shards Cancer Center Symposium, Gainesville, FL. (October 11-12, 2001) < <a href="http://medinfo.ufl.edu/cme/grounds/cancer/reddy/index.html">http://medinfo.ufl.edu/cme/grounds/cancer/reddy/index.html</a> > (last visited January 11, 2005), submitted herein as Parts A and B.	
	8	Song et al., "Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg," Blood. Vol. 105, No. 4 pgs. 1546-1548 (2005).	
	9	Supplementary European Search Report corresponding to European Patent Application No. 05732213.3 - 2402, filed March 30, 2005 by Lazarus et al., dated October 23, 2007.	
	10	Written Opinion of the International Searching Authority corresponding to International Patent Application No. PCT/CA2005/000472 dated July 27, 2005.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.